| 22.12 0.25 (1.14%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.53  |
1-year : | 33.96 |
| Resists | First : | 26.14 |
Second : | 29.07 |
| Pivot price | 23.85 |
|||
| Supports | First : | 21.38 | Second : | 17.79 |
| MAs | MA(5) : | 22.99 |
MA(20) : | 24.53 |
| MA(100) : | 29.63 |
MA(250) : | 30.46 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 26.3 |
| RSI | RSI(14): 32.5  |
|||
| 52-week | High : | 42.47 | Low : | 20.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ARWR ] has closed above bottom band by 18.5%. Bollinger Bands are 31.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.93 - 23.11 | 23.11 - 23.24 |
| Low: | 21.02 - 21.22 | 21.22 - 21.35 |
| Close: | 21.61 - 21.92 | 21.92 - 22.13 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Fri, 26 Apr 2024
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars - Business Wire
Wed, 24 Apr 2024
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results - Business Wire
Wed, 24 Apr 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney ... - Business Wire
Tue, 16 Apr 2024
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 6.6 ... - Yahoo Finance
Wed, 03 Apr 2024
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
Mon, 01 Apr 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is largely controlled by institutional shareholders who own 63% of the company - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 124 (M) |
| Held by Insiders | 1.1895e+008 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 8,840 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.8535e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -163.4 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 845.2 % |
| Return on Equity (ttm) | -24.7 % |
| Qtrly Rev. Growth | 1.8174e+008 % |
| Gross Profit (p.s.) | -130.98 |
| Sales Per Share | -147.56 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -196 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -1.2 |
| Price to Book value | 0 |
| Price to Sales | -0.15 |
| Price to Cash Flow | 10.68 |
| Dividend | 0 |
| Forward Dividend | 8.87e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|